Asthma Drugs Market Size To Hit US$ 34.28 Billion By 2030

The global asthma drugs market size is expected to hit around USD 34.28 billion by 2030 and progressing a CAGR of 5.2% over the forecast period 2022 to 2030.

The on asthma drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1225

Scope of the Asthma Drugs Market

Report Highlights	Details
Market Size	USD 34.65 Billion by 2030
Growth Rate	CAGR of 5.2% From 2022 to 2030
Base Year	2021
Historic Data	2017 to 2021
Forecast Period	2022 to 2030
Segments Covered	Medication, Mode of Administration, Source, Organization Type, Application
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

A recent report provides crucial insights along with application based and forecast information in the Global Asthma drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Asthma drugs market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Asthma drugs market are included as given below:

Asthma drugs Market Key Players

GlaxoSmithKline
Pfizer
Vectura Group
Boehringer Ingelheim
Roche
Novartis
Merck
AstraZeneca
Teva Pharmaceutical

Market Segments

By Medication

Quick Relief Medications
Long-term Control Medications
Others

By Mode of Administration

Tablets and Capsules
Liquids
Inhalers
Injections
Sprays and Powders

By Source

Environmental
Generic

By Organization Type

Public
Private

By Application

Pediatric
Adults
Adolescent

By Geography

North America
- - U.S.
  - Canada
Europe
- - Germany
  - France
  - United Kingdom
  - Rest of Europe
Asia Pacific
- - China
  - Japan
  - India
  - Southeast Asia
  - Rest of Asia Pacific
Latin America
- - Brazil
  - Rest of Latin America
Middle East & Africa (MEA)
- - GCC
  - North Africa
  - South Africa
  - Rest of Middle East & Africa

Report Objectives

To define, describe, and forecast the global asthma drugs market based on product, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the asthma drugs market

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Asthma Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Asthma Drugs Market

5.1. Covid-19: Asthma Drugs Industry Impact
5.2. Asthma Drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Asthma Drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Asthma Drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Asthma Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of asthma, along with increase in ageing population
6.1.1.2. Increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness
6.1.2. Market Restraints
6.1.2.1. Stringent government regulatory requirement for the approval of asthma drugs
6.1.3. Market Opportunities
6.1.3.1. Major companies are focusing on broadening their product portfolio

Chapter 7. Global Asthma Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Asthma Drugs Market Revenue by Market Players (2017 - 2020)
7.1.1.2. Asthma Drugs Market Revenue Market Share by Market Players (2017 - 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Process Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Asthma Drugs Market, By Medication Type

8.1. Asthma Drugs Market, by Medication Type, 2017-2030
8.1.1. Quick Relief Medications
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Long-term Control Medications
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Asthma Drugs Market, By Mode of Administration

9.1. Asthma Drugs Market, by Mode of Administration, 2017-2030
9.1.1. Tablets and Capsules
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Liquids
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalers
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Injections
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Sprays and Powders
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Asthma Drugs Market, By Source

10.1. Asthma Drugs Market, by Source, 2017-2030
10.1.1. Environmental
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Generic
10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Asthma Drugs Market, By Organization Type

11.1. Asthma Drugs Market, by Application, 2017-2030
11.1.1. Public
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Private
11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Asthma Drugs Market, By Application

12.1. Asthma Drugs Market, by Application, 2017-2030
12.1.1. Pediatric
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Adults
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Adolescent
12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Asthma Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Medication Type (2017-2030)
13.1.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.1.3. Market Revenue Forecast by Source (2017-2030)
13.1.4. Market Revenue Forecast by Organization Type (2017-2030)
13.1.5. Market Revenue Forecast by Application (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Medication Type (2017-2030)
13.2.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.2.3. Market Revenue Forecast by Source (2017-2030)
13.2.4. Market Revenue Forecast by Organization Type (2017-2030)
13.2.5. Market Revenue Forecast by Application (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Medication Type (2017-2030)
13.3.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.3.3. Market Revenue Forecast by Source (2017-2030)
13.3.4. Market Revenue Forecast by Organization Type (2017-2030)
13.3.5. Market Revenue Forecast by Application (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Medication Type (2017-2030)
13.4.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.4.3. Market Revenue Forecast by Source (2017-2030)
13.4.4. Market Revenue Forecast by Organization Type (2017-2030)
13.4.5. Market Revenue Forecast by Application (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Medication Type (2017-2030)
13.5.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.5.3. Market Revenue Forecast by Source (2017-2030)
13.5.4. Market Revenue Forecast by Organization Type (2017-2030)
13.5.5. Market Revenue Forecast by Application (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Pfizer
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Product Type
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. GlaxoSmithKline
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Product Type
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. Novartis
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Product Type
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Merck
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Product Type
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Boehringer Ingelheim
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Product Type
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. AstraZeneca
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Product Type
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Roche
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Product Type
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Teva Pharmaceutical
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Product Type
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. Vectura Group
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Product Type
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies